Shanghai Junshi Biosciences Co., Ltd. SHJBF
Set alert
3.35 USD 0.00 0.00%
At close · Oct 29
3.08 Day range 3.08
2.99 52-week range 4.23
- YTD
- +8.77%
- 1 year
- -20.80%
- Open
- 3.08
- Prev close
- 3.35
- Mkt cap
- 3.44B
- Vol
- 100
- Avg vol
- 0
- EPS
- -0.12
- P/E
- 0.00
More statistics
- Low
- 3.08
- High
- 3.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 27, 2026 | Mar 31, 2026 | — | -0.0029 | — | — |
| Feb 27, 2026 | Dec 31, 2025 | — | -0.0386 | — | — |
| Oct 28, 2025 | Sep 30, 2025 | — | -0.02528 | — | — |
| Aug 26, 2025 | Jun 30, 2025 | — | -0.0251 | — | — |
| Apr 25, 2025 | Mar 31, 2025 | — | -0.03306 | — | — |
News
- Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Stock Short Interest Declines 80.0%
- Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
- Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
- Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
- Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
- Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
- Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
- Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
- Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
Your note
Sign in to keep a note on SHJBF — it syncs with the Stock Master app.